Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting
opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo. The
primary objective of this Phase 3 long-term safety study is to compare alvimopan with placebo
for safety and tolerability in the treatment of OBD. Participants will be required to attend
8 clinic visits over approximately 1 year.